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ABSTRACT

Although corporate practices play a substantial role in shaping he
behavior, public health researchers have rarely systematically studie
as a social determinant of health. We consider case studies of three p
fat, a food additive and a preservative; Vioxx, a pain killer; and
vehicles - to illustrate the role of corporate policies and practices in
of health and disease and the implications for health policy. In recen
health advocates, researchers, and lawyers have used strategies to red
health impact of corporate practices. Systematic analysis of these ex

insights that can guide the development of health policies that increa
for primary prevention by discouraging harmful corporate practice
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INTRODUCTION

Recently, policy makers, the media, advocates, a
called attention to the impact of corporate activ
disease in the United States. High-profile cases t
public discourse include the tobacco settlement t
provide compensation to states for tobacco-rela

spread debate over the responsibility of the

industry for the current epidemic of obesity, an
drug company profits and harmful product sid

prosecutions of corporate executives have po
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about corporate responsibility. Controversy about corporations and

corporate practices has reignited a perennial American conflict
regarding appropriate roles for government and markets in political
life and in public health.
Within public health, some have urged health professionals to

engage corporations to improve health (i). Few public health

commentators, however, have systematically examined corporate
practices as social determinants of health or assessed their implica-

tions for health policy. While researchers have examined the

occupational and environmental health consequences of corporate
policies (2), very little work has focused on the cumulative impact of
consumer exposures to corporate policies. Current interest in the role

of social determinants in shaping illness and health has focused
on structural characteristics such as poverty, inequality, and racism
(3-5). The research that has considered the impact of corporate activity

on health has usually examined the health consequences of a single
product or a corporate practice rather than the patterns of behavior by
corporations and governments across a variety of industries.
In our view, a systematic investigation of the impact of corporate

decisions on health may yield insights that can guide prevention
policy. In this review, we consider how fundamental factors such as
the current relationship between markets and government influence
corporate policies and in turn how these policies influence health
behavior. Our primary interest is in corporate practices, defined as
the business and political activities of corporations. These practices

result from companies' decisions about the production, pricing,
distribution, and promotion of their products and from their political
efforts to create an environment favorable for their businesses. Our

goals are to assess the role of corporate practices in determining
health, examine their implications for health policy, and suggest
directions for policy and research. More broadly, we hope to widen
the discussion on social determinants to include corporate practices
as a modifiable influence on population health.
Recent literature on social and policy determinants of health

(6-1 1 ) and the authors' ongoing research (12) informs this

inquiry. Corporate practices can both benefit and harm health.

Changes in food production and marketing in the first part of the
20th century eliminated most malnutrition in the United States and

products developed by the pharmaceutical industry have saved
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millions of lives, as two examples. A better understanding of what

leads a company or an industry to choose health-promoting vs
health-damaging practices may help to identify new opportunitie
for policies that encourage primary prevention.
TRANS FATS, V/OXX, AND SPORTS UTILITY VEHICLES: THE
IMPACT OF CORPORATE PRACTICES ON HEALTH

To understand how corporate practices inf

health, we consider three products that have at

attention.

Trans Fats

In 1994, the Center for Science in the Public Interest, a national
advocacy organization, petitioned the Food and Drug Administration (FDA) to require that food manufacturers label the trans fatty
acid (trans fat) content of their food products. The petition was
based on research showing that replacing trans fat with healthier oils

could prevent 30,000-100,000 premature cardiovascular deaths in
the United States each year (13,14). Some researchers have suggested
that replacing trans fatty acids with healthier alternatives could
reduce the incidence of Type 2 diabetes in the US by as much as 40%

(15,16).

Artificial trans fats are used to enhance the crispness, stability, and

flavor of many processed foods (17). By the late 1990s, 40% of US

supermarket products contained trans fats. When evidence of

harmful effects began to emerge in the early 1990s, sectors of the
food industry chose different responses. Some producers rejected the
claim that trans fats were harmful and sought to delay any regulatory

action by calling for further research (18). Throughout the 1990s,
food industry groups opposed new FDA regulations on trans fats
(19). Other companies, however, accepted the call for labeling and
looked for ways to reduce the amount of trans fats so that their labels

might show lower levels. Yet others, European food companies,
moved to substitute safer ingredients for trans fats, demonstrating
that companies might opt for health-enhancing practices (19).
In 1999, despite the opposition of the food industry, the FDA
proposed to require trans fatty acid content on the standard food
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label. The agency claimed that strengthening food labeling was likely
to yield significant health and economic benefits, saving as many as

5,600 lives and $8 billion a year (20). Three years later, the US

Institute of Medicine could not determine a healthful limit of trans

fat and urged action to reduce its presence in the American diet (21).
In January 2006, the FDA rule requiring trans fats content on food
labels went into effect, but the FDA turned down requests to ban the
additive altogether. More recently, several cities and states have
banned trans fats in restaurant food.
Vioxx

Merck Pharmaceuticals obtained FDA approval to market the
painkiller Vioxx (generic name, rofecoxib) in 1999. Merck marketing promised that Vioxx would bring pain relief to people with
arthritis without the gastrointestinal side effects associated with
other medications. Five years later, after more than $10 billion in

sales, Merck withdrew Vioxx from the market because a study

showed that it doubled the risk of heart attacks and strokes in longterm users (22). By then, more than 20 million people had taken the
drug and thousands may have experienced adverse events, including
deaths, attributable to Vioxx (23).
Why did so many people take a drug that turned out to be unsafe?
First, Merck benefited from a drug-testing system that relied heavily
on industry studies rather than independent review - a testing regime

developed at the behest of a politically powerful industry (22,23).
Second, Merck invested hundreds of millions of dollars in promoting
Vioxx. In 1997, after a decade of pressure by the drug industry, the

FDA issued guidelines that relaxed restrictions on advertising
prescription drugs directly to consumers (24). By 2001, spending
by pharmaceuticals on direct-to-consumer advertising had more than

doubled (24). In 6 years, Merck spent more than $500 million

advertising Vioxx to consumers (23) and in 2003 alone, more than
$500 million on Vioxx ads for physicians (25).
The company also developed an aggressive training program for
its sales force. A training video told its sales representatives that the

drug did not cause heart attacks and encouraged them to avoid
questions on that topic (26). Merck's promotional campaigns and
advertisements led many consumers and physicians to believe that
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Vioxx and other COX-2 inhibitors (the class of drugs that
Vioxx) were superior painkillers to much less expensive but
effective over-the-counter alternatives (25).

Faced with mounting evidence regarding the dangers of Vioxx

FDA adopted a policy of watchful waiting (23), despite the f

one FDA scientist estimated that Vioxx was associated with more

than 27,000 heart attacks or deaths linked to cardiac problems (27).
Finally, Merck ignored warning signs about cardiovascular side
effects. Prior to FDA approval, for example, researchers discovered
that COX-2 inhibitors interfere with enzymes that prevent cardio-

vascular disease (22). Another study in 2000 found that people

taking Vioxx had three times as many cardiovascular events as those

taking Naproxen, another pain reliever. Merck attributed these
results to the heart-protective effects of Naproxen rather than the
harmful effects of Vioxx (22). Finally, after another study showed
serious cardiovascular problems in those who had taken Vioxx for
more than 18 months (27), Merck pulled the drug from the market.
More recently, some researchers have accused Merck of misrepre-

senting earlier safety trials that revealed harmful side effects

associated with Vioxx use of less than 18 months (28).
Sports Utility Vehicles

From the early 1990s to 2005, sports utility vehicles (SUVs) were the

best-selling and most profitable vehicles made by the US auto
industry. SUVs are characterized by a pick-up truck underbody, high

ground clearance, enclosed rear cargo area, and availability of fourwheel drive (29). SUVs, together with pick-up trucks and mini vans,
are considered "light trucks", a category that has separate safety and
fuel efficiency standards than passenger cars. By 2000, light trucks
accounted for 40% of US motor vehicles, double the 1980 rate (30).

SUVs pose several health and environmental problems. First,
because of their high center of gravity, they are three times more
likely to roll over and the rate of occupant fatalities in these rollovers

is almost three times higher than for passenger cars (31). Second,
because of their weight and design, SUVs are more likely than sedans
to kill the occupants of cars and pedestrians they hit. An analysis of
US traffic fatalities from 1995 to 2001 found that each SUV occupant

fatality averted because of the greater weight comes at a cost of 4.3
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additional crashes that involve deaths of car occupants, pedestrians,
bicyclists, or motor cyclists (32). Third, SUVs are harder to steer,
take longer to stop, and give their drivers a false sense of security that
leads to riskier driving (29). Fourth, because of high fuel needs, SUVs

produce more pollution than passenger cars, contributing to
respiratory disease, cancer, and other conditions. SUVs also release
up to 47% more CO2 than sedans (33), thus contributing to global
warming (34).
Based on a review of scientific and government reports, Bradsher
estimated that SUVs account for roughly 3,000 annual excess deaths

in the United States (29). Recent improvements in SUVs have
reduced some hazards, although as older vehicles move into the
second-hand market, characterized by riskier drivers and poorer
maintenance, the SUV death toll may increase (35).

SUVs came to the US auto market through an opportunity created

by an exemption from new fuel efficiency standards, won by
automakers in 1975. Since then, the auto industry has used its
influence in Washington to oppose changes in fuel standards for
SUVs and light trucks, despite the existence of technologies that
could improve their efficiency (36). From 1996 to 2000, Congress
passed budgets that prohibited spending any money on fuel-economy

research (29), ensuring that no new evidence would be available to

set new fuel standards.

SUVs and pick-ups were the most profitable auto industry
products because of trade protection against imported SUVs. Their

simple design led to unit profits 10-12 times higher than for

conventional cars. The auto industry, the nation's largest advertiser,
also promoted SUVs heavily, spending more than $9 billion on SUV

ads between 1990 and 2001 - ads wrongly suggesting that SUVs
were safer than passenger cars (37). Once again, profitability

trumped health, although in this case some analysts argue that US
auto makers' short-term focus on profits actually harmed long-term
profitability as changing economic conditions reduced the demand
for SUVs (37).
HOW CORPORATE PRACTICES INFLUENCE HEALTH

These stories illustrate the ways in which specific corpor

intended to achieve industry goals can result in action
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population health. Corporate managers have made dec

have contributed to tens of thousands of preventable deaths
and illnesses. But in each case, advocacy, government regu
market forces ultimately reduced the threat to population h

suggest that the systematic investigation of how compa

decisions that affect health can help identify earlier opportu

primary prevention, thus avoiding preventable deaths.

For all three products, in the absence of safety evidence, c

practices tried to maximize financial return. Adding tr

thousands of processed foods gave the food industry more f

in retail markets (e.g., longer shelf lives) while mag

cardiovascular risk for consumers. For Vioxx and SUVs,
advertising of unsafe products increased the population
amplifying negative impacts on health.
In each case, industries conducted extensive public rel

lobbying campaigns, and went to court to defeat

government regulation, extending both the period of pr
and adverse health impacts. Finally, Ford, General Moto

and major food companies paid scientists to conduct r
support their positions, contributing to doubt about th
that many public health experts believed justified re
protect health.
If trans fat, Vioxx, and SUVs were aberrations, they would be
alarming but less worthy of analysis. Recent scientific and popular
work suggests, however, that corporations regularly make decisions
that adversely affect health and that their practices have a substantial

impact on US mortality and morbidity (21,29,38-42). For example,
the tobacco and alcohol industries target advertising at young people
and heavy users, increasing the harm to health (43,44). The food
industry modifies its products by increasing portion size (45) and
adding sweeteners and fats, (46,47) contributing to obesity and
diabetes. The tobacco, automobile, and firearm industries make

campaign contributions, lobby, and go to court to prevent the
government from passing stricter safety standards for their products

(36,48,49).

The role of corporations in our daily lives and in the governance of

the United States has increased. Between the 1992 and 2004
elections, campaign contributions from the pharmaceutical and the
food and beverage industries doubled (50). Between 1998 and 2005,
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food stores' spending on lobbying increased fivefold and pharmaceutical manufacturers tripled their spending (50). Since 2000, the
number of registered lobbyists in Washington has doubled (51),
providing corporations with increased contact with policy makers and

greater opportunity to influence legislation. Between 1975 and 2001,
total US spending on advertising as a percentage of gross domestic
product more than doubled (52). Corporations have also penetrated
more sectors of public life, for example, schools and other public
places have become important sites for advertising (53), providing
greater opportunities to promote health-damaging behavior.

In the political sphere, as a result of increased lobbying and
campaign contributions, many areas of public health oversight have
been deregulated and the staff available to monitor industry practices

has been reduced (54-56). At the behest of lobbyists, 22 states have
banned obesity-related liability lawsuits against fast food restaurants
(57), and in its first term, the Bush Administration dropped 31 of 85

proposed auto safety rules from the National Highway and Auto
Safety Administration's agenda (56).
In the personal sphere, increased advertising has doubled the
number of television commercials viewed each year by the average
American child, from about 20,000 in 1970 to 40,000 in 2000 (58).

Advertisements for obesogenic processed foods are the most

common television ads aimed at children (59). Increasingly, major

corporations like McDonald's and Starbucks provide a place

away from home and work where people can socialize and consume
high-fat products (60).

CORPORATE PRACTICES AND THE SOCIAL PRODUCTION OF
POPULATION HEALTH

In past decades, health researchers have disagree
important causes of morbidity and mortality an
prevention priorities. The dominant view in the U
individual behavior and lifestyle are the primary
nants of health (61,62), suggesting that the goal of

harmful behaviors. Some US and European resea
argue that social structures and the distribution of

are the fundamental causes of disease, and that
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factors are needed to achieve improvement in populat
(10,11,63,64).
In our view, a focus on corporate behavior provides

ground for these two approaches. It suggests a policy par

aims to encourage corporate practices that promote
behavior. As corporate practices result from specific
they may be more readily changed than underlying

economic structures in which they are embedded. They o
immediate opportunities for health promotion than thos

to change more entrenched structures. While it is t

corporations, like individuals, make decisions constraine
social and economic context, identifying policies that mak
for corporations to choose health should be a public healt

Strong national standards on pollution control, for

would make it easier for automakers to produce for the
market rather than separately meet California's more
requirements (36).

To shift the focus of public health policy from individual
to corporate practices will require an elucidation of the p
which corporate decisions structure the context in which

choose behaviors and products. To illustrate, few individ

"Today, I am going to consume an extra-large portio
fructose corn syrup" (a sweetener linked to obesity and

"I'm going to buy a polluting vehicle more likely to kill or i

neighbors." Rather, these choices are made in a marketp
produces and advertises certain options and suppresses o
within a political system where certain stakeholders
power and influence than others.
In order to increase opportunities for primary preven

changes are needed: a re-conceptualization of "lifest

focused policy agenda that makes it easier for corporate m
choose health-promoting practices.
BEYOND LIFESTYLE

Historically, health researchers have regarded

of behavioral choices in multiple arenas

physical activity), influenced by underlying

tics (e.g., orientation to risk, self-efficacy
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sociologists from Weber on have seen lifestyle as a socially
determined pattern of consumption or marker of status (67,68). By
regarding lifestyle as the consequence of socially constructed choices,

it is possible to identify policies that will facilitate healthier lifestyle options.

Free market proponents argue that individuals should have the
right to choose what they consume without interference from a
"nanny state" (69), suggesting that lifestyle choices are made in a
vacuum. In fact, lifestyle choices are often the direct result of

corporate decisions. No consumer ever entered a restaurant

demanding a portion of trans fats. Rather, food companies constrain

consumer options through decisions made primarily to increase
profits. By exposing corporations as the the real "nannies" who
persuade children to eat to obesity, drivers to find their inner id
behind the wheel, or patients to solve their social problems with a
new drug, health professionals can reframe the discussion about who
can be trusted to look after the public's health.
Traditional market proponents have accepted that government has
some right to intervene in markets: for example, to ensure that
consumers have information to make informed choices, to protect
vulnerable groups such as children, or to return unintended costs of a
product ("externalities") from tax payers to producers. Recently,
however, more ardent-free market advocates have challenged even
these roles, a position some label "market fundamentalism" (70). By
encouraging more discussion on these issues, health professionals
may be able to reframe policy debates to lead to decisions that better
protect health.
A POLICY AGENDA FOR HEALTH PROMOTING CORPORATE
PRACTICES

Public health advocates have for the most part
governing corporate practices one product, company,

time. They have advocated strategies, including pub
enable individual consumers to make more inform

and legal mandates to label products truthfully
premise that consumers have a right to know (
of tobacco, alcohol, and high-calorie, low-nutrie
in order to make them less available. Others h
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banning products like flavored cigarettes, designed to appeal to young

people (79), or food advertisements for children (80) or requiring
higher fuel and safety standards for SUVs in order to reduce their
harmful impact (81).

Some advocates have switched from legislative to litigation
strategies. Consumer lawsuits have targeted many corporations
Many believe that litigation is particularly effective in getting

corporate attention. Beginning with the lawsuits against Big Tobacc
in the 1970s, a cadre of lawyers has emerged and shared lessons from

their battles against alcohol, automobile, food, gun, pharmaceutical
and tobacco industries (82-84). Public health litigators assert that
courts are an important arena in which to seek justice, educate the
public, win resources for health promotion, and force companies t
change corporate practices by returning externalized costs to their

balance sheets.

While each of these strategies has produced some significant
public health advances, in the long run, this piecemeal approach
seems inadequate to the task of promoting population health and
realizing opportunities for primary prevention. Just as researchers
and advocates in the occupational and environmental health fields
have called for moving beyond regulation of a single substance at a

time, often only after a body count has demonstrated damage
(85,86), public health policy makers concerned about corporate
practices need to consider a more comprehensive approach.
A broader agenda could serve to unify many disparate strands of
current advocacy, bring together a more cohesive and powerful
coalition to advocate in the political arena, and help reframe public
debate in more favorable terms. Such an agenda would use language
and concepts that appeal to many Americans (87,88) and provide
links to other major public issues such as campaign finance and
electoral reform, reduction of corporate crime, health care coverage,
and consumer protection.
While the specifics of such a policy agenda can only be forged by

key stakeholders - policy makers, public health professionals,

advocacy organizations, and citizens - we suggest one approach in

order to stimulate discussion.

1. Provide consumers with a right to know the health consequences

of legal products and companies with a duty to disclose such
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information. Free market ideology assumes that all parties to
commercial transactions have equal information; however, in
practice, "buyer beware" is a common experience. Extending the

right to know and the duty to disclose to consumer products
beyond the weak protections now offered could provide a legal
framework for re-defining consumer rights and better balancing
the obligations of government and markets. By making it more
difficult for producers to externalize the health costs of their
products, it might be possible to change the decision-making

process by which corporate managers now opt for harmful

practices.
2. Protect children and other vulnerable populations against targeted
advertising that promotes unhealthy behavior. Most Americans

oppose such marketing and many other free market nations
restrict such practices. National legislation to protect children
could encourage debate on the costs and benefits of recent efforts
to extend free speech protection to commercial speech (89,90) and
unify advocacy across several industries.
3. Support measures to level the political playing field. Meaningful
campaign finance reform, higher ethical standards for elected
officials, more stringent oversight of lobbying, and stronger voter

rights will help to make it easier for public health advocates to
gain electoral, legislative, or litigation support for health-promoting policies and to encourage healthier corporate practices. To
date, organized public health has rarely made support of such
reforms a priority.

4. Increase sanctions for deliberate distortions of science designed

to protect corporate interests. Industry campaigns to withhold damaging scientific data and to create scientific uncertainty
have hampered efforts to protect public health. By increasing
professional, academic, and legal sanctions for such action, it may
be possible to make it easier for scientists to resist such pressures.

5. Such an agenda could significantly strengthen fragmented
approaches to encouraging healthier corporate practices, provide

a coherent alternative to market advocates who seek to diminish

the public role in health, and support the emergence of a social
movement that seeks to re-define corporate responsibility (1).
Such movements have been the foundation for previous public

health advances.
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CONCLUSION

In summary, we argue that corporate practices a

determinant of health, and those policies tha
corporate practices are likely to improve popu
recent years, public health advocates have dev

to bring about policy changes, efforts often opp
and its supporters. A systematic study of both t
inform more effective public health policy an

current political climate, these proposals may

even naive. In a society that seeks to protect pub
are common sense.
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